Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) in Non-Hospitalized COVID-19 Patients
As part of the ACTIV-2/A5401 randomized clinical trial (NCT04518410), participants with symptomatic SARS-CoV-2 infection 19 at low risk for progression were randomized 1:1 to subcutaneously administered BMS-986414 (C135-LS) 200 mg plus BMS-986413 (C144-LS) 200 mg (BMS agent) versus placebo. We performed targeted Spike (S) gene next-generation sequencing to detect BMS specific resistance mutations.